

Epitope Mapping of Monoclonal Antibody PMAb-48 Against Dog Podoplanin

Shinji Yamada,¹ Mika K. Kaneko,¹ Shunsuke Itai,^{1,2} Yao-Wen Chang,¹ Takuro Nakamura,¹ Miyuki Yanaka,¹ Satoshi Ogasawara,³ Takeshi Murata,³ Hiroaki Uchida,⁴ Hideaki Tahara,⁴ Hiroyuki Harada,² and Yukinari Kato^{1,5}

Podoplanin (PDPN), a type I transmembrane sialoglycoprotein, is expressed on normal renal podocytes, pulmonary type I alveolar cells, and lymphatic endothelial cells. Increased expression of PDPN in cancers is associated with poor prognosis and hematogenous metastasis through interactions with C-type lectin-like receptor 2 (CLEC-2) on platelets. We previously reported a novel PMAb-48 antibody, which is an anti-dog PDPN (dPDPN) monoclonal antibody (mAb) recognizing PDPN expressed in lymphatic endothelial cells. However, the binding epitope of PMAb-48 is yet to be clarified. In this study, an enzyme-linked immunosorbent assay and flow cytometry were used to investigate epitopes of PMAb-48. The results revealed that the critical epitope of PMAb-48 comprises Asp29, Asp30, Ile31, Ile32, and Pro33 of dPDPN.

Keywords: dog podoplanin, dPDPN, monoclonal antibody, epitope mapping

Introduction

PODOPLANIN (PDPN) is expressed in normal tissues such as renal podocytes, pulmonary type I alveolar cells, lymphatic endothelial cells, chondrocytes, myofibroblasts, and mesothelial cells.⁽¹⁾ However, higher expression of PDPN has been observed in different tumor types, including squamous cell carcinoma,⁽²⁾ melanoma,⁽³⁾ glioblastoma,⁽⁴⁾ and mesothelioma.⁽⁵⁾ Recent clinical studies have provided evidence of associations between increased PDPN expression, poor prognosis, and cancer metastasis,⁽⁶⁾ indicating that the establishment and production of anti-PDPN monoclonal antibodies (mAbs) are necessary for developing novel therapeutic strategies against cancer development and progression to metastasis.⁽⁷⁾

Dog podoplanin (dPDPN) was first reported as gp40.⁽⁸⁾ Recently, we developed two mAbs, PMAb-38^(2,3,9) and PMAb-48,⁽¹⁰⁾ both of which specifically recognize dPDPN. Tyr67 and Glu68 were determined to be the critical features of the epitope of PMAb-38.⁽¹¹⁾ Using point mutants of dPDPN, the present study aimed to investigate the epitope of PMAb-48 by enzyme-linked immunosorbent assay (ELISA) and flow cytometry.

Materials and Methods

Cell lines

CHO-K1 cells were transfected with the dPDPN-MAP tag plasmid using Lipofectamine LTX (Thermo Fisher Scientific, Inc., Waltham, MA).⁽⁹⁾ CHO/dPDPN cells were cultured in an RPMI 1640 medium (Nacalai Tesque, Inc., Kyoto, Japan), supplemented with 10% heat-inactivated fetal bovine serum (Thermo Fisher Scientific, Inc., Waltham, MA), 100 U/mL penicillin, 100 µg/mL streptomycin, and 25 µg/mL amphotericin B (Nacalai Tesque, Inc.), and incubated at 37°C in a humidified atmosphere of 5% CO₂ and 95% air.

Enzyme-linked immunosorbent assay

Synthesized dPDPN peptides (PEPScreen; Sigma-Aldrich Corp., St. Louis, MO) were immobilized on Nunc Maxisorp 96-well immunoplates (Thermo Fisher Scientific, Inc.) at 5 µg/mL for 30 minutes. After blocking with SuperBlock T20 (phosphate-buffered saline [PBS]) Blocking Buffer (Thermo Fisher Scientific, Inc.), the plates were incubated with purified PMAb-48 (10 µg/mL), followed by a 1:2000 dilution of peroxidase-conjugated anti-mouse IgG (Agilent Technologies, Inc., Santa

¹Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.

²Department of Oral and Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

³Department of Chemistry, Graduate School of Science, Chiba University, Chiba, Japan.

⁴Division of Bioengineering, Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

⁵New Industry Creation Hatchery Center, Tohoku University, Sendai, Japan.

Clara, CA). The enzymatic reaction was conducted using 1-Step Ultra TMB-ELISA (Thermo Fisher Scientific, Inc.). Optical density was measured at 655 nm using an iMark microplate reader (Bio-Rad Laboratories, Inc., Berkeley, CA). These reactions were performed at 37°C with a total sample volume of 50–100 μ L.

Flow cytometry

Cells were harvested after brief exposure to 0.25% trypsin/1 mM ethylenediaminetetraacetic acid (Nacalai Tesque, Inc.). After washing with 0.1% bovine serum albumin in PBS, the cells were treated with PMab-48 (10 μ g/mL) or PMab-48 (10 μ g/mL) plus peptides (10 μ g/mL) for 30 minutes at 4°C, followed by treatment with Alexa Fluor 488-conjugated anti-mouse IgG (1:1000; Cell Signaling Technology, Inc., Danvers, MA). Fluorescence data were acquired using the cell analyzer SA3800 (Sony Corp., Tokyo, Japan).

Results

We previously developed a novel PMab-48 mAb that exhibits high specificity and sensitivity against dPDPN and is highly suitable for detection of lymphatic endothelial cells in immunohistochemical analysis.⁽¹⁰⁾ PMab-48 can be used to detect dPDPN expressed by squamous cell carcinomas.⁽¹⁰⁾ These findings suggest that PMab-48 epitope mapping could be a promising target for PDPN-based diagnosis and cancer therapy.

In this study, we synthesized a series of point mutants of dPDPN peptides from the 26th to the 40th amino acid (Table 1). Using ELISA, PMab-48 detected V26A, R27A, P28A, G34A, V35A, E36A, D37A, S38A, V39A, and V40A; in contrast, PMab-48 did not react with D29A, D30A, I31A, I32A, or P33A, indicating that the DDIIP sequence is a critical epitope of PMab-48.

Next, we performed a blocking assay using flow cytometry. PMab-48 reacted with the CHO/dPDPN cell line

TABLE 1. DETERMINATION OF PMAB-48 EPITOPE BY ENZYME-LINKED IMMUNOSORBENT ASSAY

| Mutation | Sequence | PMab-48 |
|-----------|------------------|---------|
| Wild type | VRPDDIIPGVEDSVV | +++ |
| V26A | ARPDDIIPGVEDSVV | ++ |
| R27A | VAPDDIIPGVEDSVV | + |
| P28A | VRADDIIPGVEDSVV | +++ |
| D29A | VRPADIIIPGVEDSVV | — |
| D30A | VRPDAIIPGVEDSVV | — |
| I31A | VRPDDAIIPGVEDSVV | — |
| I32A | VRPDDIIAPGVEDSVV | — |
| P33A | VRPDDIIAGVEDSVV | — |
| G34A | VRPDDIIPAVEDSVV | ++ |
| V35A | VRPDDIIPGAEDSVV | +++ |
| E36A | VRPDDIIPGVADSVV | +++ |
| D37A | VRPDDIIPGVEASVV | +++ |
| S38A | VRPDDIIPGVEDAVV | + |
| V39A | VRPDDIIPGVEDSAV | +++ |
| V40A | VRPDDIIPGVEDSVA | +++ |

+++ , OD₆₅₅ \geq 0.6; ++ , 0.4 \leq OD₆₅₅ < 0.6; + , 0.2 \leq OD₆₅₅ < 0.4; — , OD₆₅₅ < 0.2.




FIG. 1. Flow cytometry using PMab-48 and point mutants of dPDPN. PMab-48 or PMab-48 + peptides (WT, D29A, D30A, I31A, I32A, P33A, or V35A) were treated with CHO/dPDPN cells for 30 minutes at 4°C, followed by addition of secondary antibodies. dPDPN, dog podoplanin; WT, wild type; gray peak, negative control.

(Fig. 1). This reaction was completely neutralized by the wild-type peptide (VRPDDIIPGVEDSVV) and V35A; in contrast, D29A, D30A, I31A, I32A, and P33A did not block the reaction of PMab-48 with CHO/dPDPN, indicating that the DDIIP sequence is a critical epitope of PMab-48 (Fig. 2).




FIG. 2. Schematic illustration of the epitope recognized by PMab-48. PLAG, platelet aggregation-stimulating.

Discussion

Previously, a critical epitope of another anti-dPDPN mAb, PMab-38, was determined to comprise Tyr67 and Glu68,⁽¹¹⁾ indicating that epitopes of PMab-48 and PMab-38 are different (Fig. 2). PMab-48 reacted with lymphatic endothelial cells in immunohistochemistry,⁽¹⁰⁾ although PMab-38 did not,⁽⁹⁾ demonstrating that the N-terminal region is a more adequate epitope for detecting dPDPN of lymphatic endothelial cells probably because N-terminus might not be *O*-glycosylated.⁽¹²⁾

In contrast, PMab-38 showed cancer specificity in immunohistochemistry using canine tissues⁽²⁾ in the same pattern with anti-human PDPN (hPDPN) cancer-specific mAbs, such as LpMab-2^(7,13) and LpMab-23.^(6,14,15) We previously showed that Thr55-Leu64 peptide of hPDPN, especially *O*-glycan attached in Thr55 and Ser56 of hPDPN, is a critical epitope of LpMab-2.⁽⁷⁾ We further showed that Gly54-Leu64 peptide of hPDPN is a critical epitope of LpMab-23.⁽¹⁵⁾ The epitope of PMab-38 for dPDPN is similar to those of LpMab-2 and LpMab-23 for hPDPN. Therefore, this kind of epitope mapping provides important evidence for clinical application of anti-PDPN mAbs.

Acknowledgments

The authors thank Noriko Saidoh, Saori Handa, and Yoshimi Nakamura for their excellent technical assistance. This research was supported, in part, by AMED under Grant Numbers: JP17am0301010 (Y.K.), JP17am0101078 (Y.K.), and JP17ae0101028 (Y.K.) and by JSPS KAKENHI Grant Number 17K07299 (M.K.K.) and Grant Number 16K10748 (Y.K.). This work was performed, in part, under the Co-operative Research Program of the Institute for Protein Research, Osaka University, CR-17-05, and by the Grant for Joint Research Project of the Institute of Medical Science, the University of Tokyo.

Author Disclosure Statement

No competing financial interests exist.

References

- Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, Schaffner G, and Kerjaschki D: Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. *Am J Pathol* 1997;151:1141–1152.
- Kaneko MK, Honma R, Ogasawara S, Fujii Y, Nakamura T, Saidoh N, Takagi M, Kagawa Y, Konnai S, and Kato Y: PMab-38 recognizes canine podoplanin of squamous cell carcinomas. *Monoclon Antib Immunodiagn Immunother* 2016;35:263–266.
- Ogasawara S, Honma R, Kaneko MK, Fujii Y, Kagawa Y, Konnai S, and Kato Y: Podoplanin expression in canine melanoma. *Monoclon Antib Immunodiagn Immunother* 2016;35:304–306.
- Kato Y, Vaidyanathan G, Kaneko MK, Mishima K, Srivastava N, Chandramohan V, Pegram C, Keir ST, Kuan CT, Bigner DD, and Zalutsky MR: Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas. *Nucl Med Biol* 2010;37:785–794.
- Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, and Nishioka Y: Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model. *Cancer Sci* 2016;107:1198–1205.
- Retzbach EP, Sheehan SA, Nevel E, Batra A, Phi T, Kato Y, Baredes S, Fatahzadeh M, Shienbaum AJ, and Goldberg GS: Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target. *Oral Oncol* 2018;78:126–136.
- Kato Y, and Kaneko MK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. *Sci Rep* 2014;4:5924.
- Zimmer G, Klenk HD, and Herrler G: Identification of a 40-kDa cell surface sialoglycoprotein with the characteristics of a major influenza C virus receptor in a Madin-Darby canine kidney cell line. *J Biol Chem* 1995;270:17815–17822.
- Honma R, Kaneko MK, Ogasawara S, Fujii Y, Konnai S, Takagi M, and Kato Y: Specific detection of dog podoplanin expressed in renal glomerulus by a novel monoclonal anti-

- body PMab-38 in immunohistochemistry. *Monoclon Antib Immunodiagn Immunother* 2016;35:212–216.
10. Yamada S, Itai S, Kaneko MK, and Kato Y: PMab-48 recognizes dog podoplanin of lymphatic endothelial cells. *Monoclon Antib Immunodiagn Immunother* 2018;37:63–66.
 11. Chang YW, Yamada S, Kaneko MK, and Kato Y: Epitope Mapping of Monoclonal antibody PMab-38 against dog podoplanin. *Monoclon Antib Immunodiagn Immunother* 2017; 36:291–295.
 12. Kaneko MK, Kato Y, Kitano T, and Osawa M: Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. *Gene* 2006;378: 52–57.
 13. Kaneko MK, Yamada S, Nakamura T, Abe S, Nishioka Y, Kunita A, Fukayama M, Fujii Y, Ogasawara S, and Kato Y: Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. *Cancer Med* 2017; 6:768–777.
 14. Yamada S, Ogasawara S, Kaneko MK, and Kato Y: LpMab-23: A cancer-specific monoclonal antibody against human podoplanin. *Monoclon Antib Immunodiagn Immunother* 2017;36:72–76.
 15. Kaneko MK, Nakamura T, Kunita A, Fukayama M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, Fujii Y, Ogasawara S, and Kato Y: ChLpMab-23: Cancer-specific human-mouse chimeric anti-podoplanin antibody exhibits antitumor activity via antibody-dependent cellular cytotoxicity. *Monoclon Antib Immunodiagn Immunother* 2017;36:104–112.

Address correspondence to:

Yukinari Kato

*Department of Antibody Drug Development
Tohoku University Graduate School of Medicine*

2-1 Seiryomachi

Aoba-ku

Sendai 980-8575

Miyagi

Japan

*E-mail: yukinarikato@med.tohoku.ac.jp;
yukinari-k@bea.hi-ho.ne.jp*

Received: January 23, 2018

Accepted: March 7, 2018